Helical Closes $10M Seed to Turn Bio Foundation Models Into Systems

Why It Matters

By operationalizing bio‑foundation models, Helical could dramatically lower the $2 billion average cost and decade‑long timelines of new drug development, reshaping pharma R&D economics. Its platform addresses a critical bottleneck—translating AI outputs into reproducible, auditable scientific decisions—potentially accelerating pipelines for the industry’s $300 billion annual R&D spend.

Key Takeaways

• Helical raised $10M seed led by redalpine, with AI CEOs as angels.
• Platform offers Virtual Lab for biologists and Model Factory for ML engineers.
• Deployed with Pfizer, compressing drug discovery from years to weeks.
• Pharma R&D exceeds $300B annually; Helical aims to cut costs, timelines.

Pulse Analysis

The rise of bio‑foundation models—AI systems trained on massive genomic, transcriptomic and proteomic datasets—has created a new frontier for pharmaceutical research. While model accuracy has reached a point where hypothesis testing becomes viable, the industry lacks the infrastructure to move from isolated notebooks to production‑grade pipelines. Helical’s answer is a unified platform that bridges the gap between model outputs and scientific decision‑making, offering a Virtual Lab for bench scientists and a Model Factory for data engineers. This dual‑surface approach promises reproducibility, auditability, and scalability across disease areas, addressing a pain point that has slowed AI adoption in drug discovery.

Helical’s early traction with top‑20 pharma players, notably a public collaboration with Pfizer on predictive safety biomarkers, demonstrates the platform’s practical impact. Customers report compressing discovery timelines from years to weeks, a claim that, if broadly validated, could shave billions off the average $2 billion cost of bringing a drug to market. By standardizing data and model access, the platform also reduces redundant effort, allowing teams to focus on hypothesis generation rather than infrastructure maintenance. Such efficiency gains are especially critical given that over 90 % of clinical candidates fail, making every week saved a potential increase in success probability.

The $10 million seed, backed by AI veterans and venture firms, signals strong investor belief in the convergence of large‑scale biological models and integrated tooling. As general‑language reasoning models begin to incorporate multimodal biological data, platforms like Helical will become essential for translating raw AI capability into actionable, regulatory‑compliant insights. This funding round builds on a prior €2.2 million (~$2.4 million) raise, positioning Helical to scale its engineering team and deepen pharma partnerships. If the company sustains its claimed acceleration, it could catalyze a broader shift toward AI‑first drug development, reshaping the competitive landscape of the $300 billion annual pharma R&D market.